ImmunityBio, Inc. (IBRX) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
ImmunityBio, Inc. (Stock Symbol: IBRX) is a leading company in the Life Sciences sector , specifically operating within the Biological Products, (No Diagnostic Substances) industry. The organization employs approximately 535 professionals worldwide . The company has established itself as a growing mid-cap opportunity with strong fundamentals.
Financial Performance & Key Metrics Analysis
Market Capitalization: $2427 million - Classified as a mid-cap growth stock with balanced risk-reward profile.
Return on Equity (ROE): 4.3% - Below-average shareholder return efficiency, indicating areas for operational improvement.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for ImmunityBio, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
ImmunityBio, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace, establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share . . The company maintains a healthy 271.4% gross margin, indicating strong pricing power and operational efficiency.